Prevalence of comorbidities in chronic obstructive pulmonary disease patients

Yin, Honglei; Yin, Shankai; Lin, Qingyan; Xu, Ying; Xu, Hongwei; Liu, Tao

doi:10.1097/md.0000000000006836

Cited by 107 publications

(87 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the exact prevalence varies between studies (Bitar, Ghoto, Dayo, Arain, & Parveen, 2017;Makarevich, Valevich, & Pochtavtsev, 2007;Parappil, Depczynski, Collett, & Marks, 2010), patients with COPD in general tend to have a greater chance of developing diabetes (type 2) with a prevalence of 18.7% in COPD patients versus 10.5% in the general population (Cazzola, Bettoncelli, Sessa, Cricelli, & Biscione, 2010;Yin et al, 2017). Persistent systemic inflammation appears to be an important mechanistic factor responsible for the progression of the two diseases (Akpinar et al, 2012;Tkacova, 2010;Yanbaeva, Dentener, Creutzberg, & Wouters, 2006), greatly increasing an individual's risk for comorbidities such as cardiovascular complications (Barnes & Celli, 2009;Cazzola et al, 2010;Vogelmeier et al, 2017).…”

Section: Copd and Diabetesmentioning

confidence: 99%

Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies

Chan

Selemidis

Bozinovski

et al. 2019

Pharmacology & Therapeutics

116

View full text Add to dashboard Cite

a b s t r a c t a r t i c l e i n f oChronic obstructive pulmonary disease (COPD) is a major incurable global health burden and is currently the 4th largest cause of death in the world. Importantly, much of the disease burden and health care utilisation in COPD is associated with the management of its comorbidities (e.g. skeletal muscle wasting, ischemic heart disease, cognitive dysfunction) and infective viral and bacterial acute exacerbations (AECOPD). Current pharmacological treatments for COPD are relatively ineffective and the development of effective therapies has been severely hampered by the lack of understanding of the mechanisms and mediators underlying COPD. Since comorbidities have a tremendous impact on the prognosis and severity of COPD, the 2015 American Thoracic Society/European Respiratory Society (ATS/ERS) Research Statement on COPD urgently called for studies to elucidate the pathobiological mechanisms linking COPD to its comorbidities. It is now emerging that up to 50% of COPD patients have metabolic syndrome (MetS) as a comorbidity. It is currently not clear whether metabolic syndrome is an independent co-existing condition or a direct consequence of the progressive lung pathology in COPD patients. As MetS has important clinical implications on COPD outcomes, identification of disease mechanisms linking COPD to MetS is the key to effective therapy. In this comprehensive review, we discuss the potential mechanisms linking MetS to COPD and hence plausible therapeutic strategies to treat this debilitating comorbidity of COPD.

show abstract

Section: Copd and Diabetesmentioning

confidence: 99%

Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies

Chan

Selemidis

Bozinovski

et al. 2019

Pharmacology & Therapeutics

116

View full text Add to dashboard Cite

show abstract

“…At admission, 23.1% of them were treated with at least 1 LABA and 24.2% were treated with at least 1 LAMA. Regarding the association of [2][3][4][5][6][7][8][9][10][11][12][13][14] .001 Education, y (n ¼ 5523) 5 [5][6][7][8][9] 5 [5][6][7][8] . Table S2).…”

Section: Pharmacologic Treatment and Therapeutic Appropriatenessmentioning

confidence: 99%

“…1,2 In older people, COPD is often accompanied by multiple comorbidities. 3 Moreover, COPD is associated with an increased risk of death, with 3 million deaths being reported globally every year. 1 The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines provide recommendations for drug treatment based on inhaled agents, with the goal to reduce symptoms, frequency, and severity of exacerbations, and to improve exercise tolerance and overall health status.…”

mentioning

confidence: 99%

“…1 However, GOLD guidelines are often not followed, with a high rate of poor adherence to recommendations 4,5 even though adherence has been associated with a reduction of health care resources use. 4 Aims for this study were as follows: (1) to report COPD prevalence in the frame of a registry of older multimorbid patients acutely hospitalized in internal medicine and geriatric wards in Italy; (2) to analyze the use of drugs specific for COPD (inhaled bronchodilators and corticosteroids) and evaluate physicians' adherence to GOLD guidelines recommendations about pharmacologic prescription and the associated clinical factors; (3) to investigate the association of COPD with major clinical outcomes throughout the posthospital follow-up observation period; and (4) to evaluate the association between adherence to guidelines' recommendations and major clinical outcomes. In order to achieve these aims, we performed an analysis of hospitalized patients with COPD in the REgistro POliterapie SIMI (REPOSI) registry.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Hospital Care of Older Patients With COPD: Adherence to International Guidelines for Use of Inhaled Bronchodilators and Corticosteroids

Proietti¹,

Agosti²,

Lonati³

et al. 2019

Journal of the American Medical Directors Association

View full text Add to dashboard Cite

Keywords:COPD older patients guidelines adherence major clinical events a b s t r a c tObjectives: We aimed to analyze the prevalence and impact of COPD in older patients hospitalized in internal medicine or geriatric wards, and to investigate adherence to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, associated clinical factors, and outcomes. Design: Data were obtained from REgistro POliterapie SIMI (REPOSI), a prospective multicenter observational registry that enrolls inpatients aged 65 years. Setting and Participants: Older hospitalized patients enrolled from 2008 to 2016 with a diagnosis of COPD. Measures: We evaluated adherence to the 2018 GOLD guidelines at admission and discharge, by examining the prescription of inhaled bronchodilators and corticosteroids in COPD patients. We also evaluated the occurrence of outcomes and its association with COPD and guideline adherence. Results: At hospital admission, COPD was diagnosed in 1302 (21.5%) of 6046 registered patients. COPD patients were older, with more impaired clinical and functional status and multiple comorbidities. Overall, 34.3% of COPD patients at admission and 35.6% at discharge were adherent to the GOLD guidelines. Polypharmacy (5 drugs) at admission [odds ratio (OR): 3.28, 95% confidence interval (CI): 2.24-4.81], a history of acute COPD exacerbation (OR: 2.65, 95% CI: 1.44-4.88) at admission, smoking habit (OR: 1.45, 95% CI: 1.08-1.94), and polypharmacy at discharge (OR: 6.76, 95% CI: 4.15-11.0) were associated with adherence to guidelines. COPD was independently associated with the risk of cardiovascular and respiratory death and rehospitalization occurrence compared to patients without COPD during follow-up. Adherence to guidelines was inversely associated with the occurrence of death from all causes (OR: 0.12, 95% CI: 0.02-0.90). Conclusions/Implications: COPD was common in older patients acutely hospitalized, showing an impaired functional and clinical status. Prescriptions for older COPD patients were often not adherent to GOLD guidelines. Poor adherence to guidelines was associated with a worse clinical status.

show abstract

“…Una gran mayoría de nuestra cohorte (78%) presentó comorbilidades asociadas, siendo la hipertensión arterial la más común. Esto coincide con los resultados de otros estudios tanto nacionales como internacionales 20,25,26 y es de suma importancia para el seguimiento de los pacientes, dado que las comorbilidades merman la calidad de vida de los enfermos de EPOC y son responsables de su mortalidad en muchos casos 27 . En cuanto al historial de exacerbaciones, casi la mitad de nuestra cohorte manifestó haber padecido alguna exacerbación durante el último año (48%).…”

unclassified

Caracterización general de los pacientes con EPOC de la Región del Maule: resultados preliminares del estudio MaulEPOC

Olloquequi

Caro

Parra

et al. 2017

Rev. chil. enferm. respir.

View full text Add to dashboard Cite

show abstract

Prevalence of comorbidities in chronic obstructive pulmonary disease patients

Abstract: Supplemental Digital Content is available in the text

Cited by 107 publications

References 35 publications

Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies

Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies

Hospital Care of Older Patients With COPD: Adherence to International Guidelines for Use of Inhaled Bronchodilators and Corticosteroids

Caracterización general de los pacientes con EPOC de la Región del Maule: resultados preliminares del estudio MaulEPOC

Contact Info

Product

Resources

About